ATE107858T1 - Pharmazeutische zusammensetzung zum abnehmen. - Google Patents

Pharmazeutische zusammensetzung zum abnehmen.

Info

Publication number
ATE107858T1
ATE107858T1 AT90907185T AT90907185T ATE107858T1 AT E107858 T1 ATE107858 T1 AT E107858T1 AT 90907185 T AT90907185 T AT 90907185T AT 90907185 T AT90907185 T AT 90907185T AT E107858 T1 ATE107858 T1 AT E107858T1
Authority
AT
Austria
Prior art keywords
slimming
pharmaceutical composition
ephedrine
human
reducing
Prior art date
Application number
AT90907185T
Other languages
English (en)
Inventor
Arne Astrup
Original Assignee
Nycomed Dak As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Dak As filed Critical Nycomed Dak As
Application granted granted Critical
Publication of ATE107858T1 publication Critical patent/ATE107858T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT90907185T 1989-07-07 1990-04-20 Pharmazeutische zusammensetzung zum abnehmen. ATE107858T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK339289A DK339289D0 (da) 1989-07-07 1989-07-07 Farmaceutisk praeparat

Publications (1)

Publication Number Publication Date
ATE107858T1 true ATE107858T1 (de) 1994-07-15

Family

ID=8122369

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90907185T ATE107858T1 (de) 1989-07-07 1990-04-20 Pharmazeutische zusammensetzung zum abnehmen.

Country Status (19)

Country Link
US (1) US5422352A (de)
EP (1) EP0480934B1 (de)
JP (1) JP2584899B2 (de)
KR (1) KR0159045B1 (de)
AT (1) ATE107858T1 (de)
AU (1) AU638992B2 (de)
CA (1) CA2063598C (de)
DE (1) DE69010336T2 (de)
DK (2) DK339289D0 (de)
ES (1) ES2055911T3 (de)
FI (1) FI920026A0 (de)
HK (1) HK1001821A1 (de)
HU (1) HU220071B (de)
LT (1) LT3536B (de)
LV (1) LV10192B (de)
NO (1) NO920051L (de)
RU (1) RU2109511C1 (de)
UA (1) UA27779C2 (de)
WO (1) WO1991000730A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5865869A (en) * 1991-08-02 1999-02-02 Ecologel Usa, Inc. Solution for plant root watering
AU4659793A (en) * 1992-06-30 1994-01-24 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Anorectic epinephrine derivatives
CA2147180A1 (en) * 1992-10-15 1994-04-28 Gokhan S. Hotamisligil Treatment of insulin resistance in obesity linked type ii diabetes using antagonists to tnf-.alpha. function
ES2094687B1 (es) * 1994-08-02 1997-12-16 S A L V A T Lab Sa Combinacion farmaceutica contra la obesidad o el sobrepeso.
FR2746644A1 (fr) * 1996-03-18 1997-10-03 Firion Jackie Produit parapharmaceutique moderateur d'appetit
US6224873B1 (en) 1996-09-30 2001-05-01 Zhishin, Llc Regulation of appetite, body weight and athletic function with materials derived from citrus varieties
CA2248854C (en) * 1996-09-30 2004-03-30 Dennis Jones The regulation of appetite, body weight and athletic function with materials derived from citrus varieties
US6635678B1 (en) 1996-12-23 2003-10-21 S.L.A. Pharma Ag Pharmaceutical composition for treating fecal incontinence
US5798101A (en) * 1997-01-22 1998-08-25 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
US6162455A (en) * 1997-01-22 2000-12-19 American Cyanamid Company Method for increasing lean meat, improving the lean meat to fat ratio and improving amino acid utilization in warm-blooded animals
US5985282A (en) * 1997-01-22 1999-11-16 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
HUP9700654A2 (hu) 1997-03-26 1999-09-28 Dezső Korbonits Teobromin tartalmú köhögéscsillapító készítmények
US6468519B1 (en) * 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
WO2000000184A2 (en) * 1998-06-26 2000-01-06 Delack Elaine A Use of histamine h2 mimicking substances for the treatment of multiple sclerosis
US7232830B2 (en) 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
US6340482B1 (en) 2000-05-18 2002-01-22 Zhishin, Llc Methods for inducing weight loss in a human with materials derived from Citrus varieties
US6113949A (en) * 1998-10-27 2000-09-05 Prolab Nutrition, Inc. Weight control product and method of treating hyperlipidemia and increasing vigor with said product
US6475514B1 (en) * 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
US6576272B1 (en) * 1999-03-05 2003-06-10 Twin Laboratories Incorporated Dietary supplement and method of using same
AU6221500A (en) * 1999-07-20 2001-02-05 Natrol, Inc. Weight control product comprising a synergistic mixture of guggul extract, phosphate salt and metabolic stimulant
CA2382666A1 (en) * 1999-08-23 2001-03-01 The Administrators Of The Tulane Educational Fund Modulation of the blood-brain barrier transporter for leptin
US6723737B1 (en) * 1999-10-20 2004-04-20 Eliezer Rapaport Methods, pharmaceutical and therapeutic compostions for administering adenosine
US7892586B2 (en) 2001-02-22 2011-02-22 Suzanne Jaffe Stillman Water containing soluble fiber
US8178150B2 (en) 2000-02-22 2012-05-15 Suzanne Jaffe Stillman Water containing soluble fiber
US7115297B2 (en) * 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
DE10011541A1 (de) * 2000-03-06 2001-09-20 Reimann Hartmut Verwendung einer Kombination aus Ephedrin und Coffein und/oder Theophyllin zur Vitalisierung von Knochenfischen, Wasserzusatz zur Vitalisierung von Knochenfischen
US6316499B1 (en) 2000-05-18 2001-11-13 Zhishin, Llc Methods for increasing the muscle mass of a human with materials derived from citrus varieties
WO2002051428A1 (fr) * 2000-12-25 2002-07-04 Shiseido Company, Ltd. Composition de parfum stimulant le systeme sympathique
US7048941B2 (en) * 2001-03-30 2006-05-23 New World Enterprizes, Inc. Chocolate composition as delivery system for nutrients and medications
WO2003022239A2 (en) * 2001-09-07 2003-03-20 Western Holdings Llc Stable water in oil aminophylline emulsions
GB0130763D0 (en) 2001-12-21 2002-02-06 Norgine Res Ltd Treatment methods
WO2003088953A2 (en) * 2002-04-19 2003-10-30 N.V. Nutricia Multiphasic diet
US8142810B2 (en) * 2002-05-30 2012-03-27 The Procter & Gamble Company Dietary method for modulating glucose metabolism and associated conditions and increasing longevity
US20040077530A1 (en) * 2002-10-18 2004-04-22 Robert Portman Composition for reducing caloric intake
US20040224031A1 (en) * 2003-05-06 2004-11-11 Antonio Zorzano Olarte Combination of amines and vanadium (IV)/(V) compounds for the treatment and/or prevention of diabetes mellitus
WO2005034650A1 (en) * 2003-10-17 2005-04-21 Diet Formulations Ltd. Weight-loss supplement
EP1684593A4 (de) * 2003-11-20 2010-02-10 Alteragon Pty Ltd Verfahren zur verringerung von fettablagerungen sowie des körpergewichts bei säugetieren und vögeln
CA2455248A1 (en) * 2004-01-29 2005-07-29 Alexander Zolotoy Oral administration of r-albuterol against obesity
US7524064B2 (en) * 2004-03-09 2009-04-28 Research Foundation Of The State University Of New York Apparatus and method for assessing retinal damage
US20060074057A1 (en) * 2004-10-04 2006-04-06 Eric Marchewitz Use of chenodeoxycholic acid for reducing adipose tissue
US20060134230A1 (en) * 2004-12-17 2006-06-22 Sal Abraham Weight loss composition and formulation
US20060204599A1 (en) * 2005-03-14 2006-09-14 Wheat Jared R Dietary supplement and method of using same
US20090214682A1 (en) * 2008-02-22 2009-08-27 Heuer Marvin A Composition and methods for weight loss in a subject
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US9610429B2 (en) * 2010-12-29 2017-04-04 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue with targeted substance delivery
NZ706326A (en) * 2012-10-08 2018-01-26 Rivalea (Australia) Pty Ltd Animal feed supplement comprising ractopamine and caffeine
US9877434B2 (en) 2013-05-30 2018-01-30 Ecologel Solutions, Llc Granular compositions and methods for drought mitigation
CA2943385C (en) * 2014-03-26 2022-06-21 Rivalea (Australia) Pty Ltd Method for improving feed efficiency in ruminants
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
EP3256004A1 (de) 2015-02-13 2017-12-20 Mars, Incorporated Zuführsystem für haustierfutter
WO2016167855A1 (en) * 2015-04-14 2016-10-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Combination of albuterol and caffeine as synergistic treatment for obesity or sarcopenia
GB201522296D0 (en) 2015-12-17 2016-02-03 Mars Inc Food product to reduce body fat
CA3140043A1 (en) 2019-05-16 2020-11-19 Nexus Pharmaceuticals, Inc. Compositions comprising ephedrine or an ephedrine salt and methods of making and using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2390164A1 (fr) * 1977-05-13 1978-12-08 Blanie Paul Association a action anti-asthmatique
FI772858A (fi) * 1977-06-03 1978-12-04 Pharmaceutical Export Promotio Avmagningsmedel och foerfarande foer framstaellning daerav
US4364922A (en) * 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US5011843A (en) * 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors

Also Published As

Publication number Publication date
RU2109511C1 (ru) 1998-04-27
CA2063598C (en) 1997-12-09
UA27779C2 (uk) 2000-10-16
EP0480934A1 (de) 1992-04-22
EP0480934B1 (de) 1994-06-29
HU220071B (hu) 2001-10-28
FI920026A0 (fi) 1992-01-03
LT3536B (en) 1995-11-27
US5422352A (en) 1995-06-06
LV10192B (en) 1995-06-20
KR0159045B1 (ko) 1998-12-01
LTIP702A (en) 1995-01-31
NO920051D0 (no) 1992-01-03
DK339289D0 (da) 1989-07-07
DK0480934T3 (da) 1994-11-07
DE69010336T2 (de) 1994-11-03
WO1991000730A1 (en) 1991-01-24
HU9200051D0 (en) 1992-06-29
NO920051L (no) 1992-01-31
JP2584899B2 (ja) 1997-02-26
ES2055911T3 (es) 1994-09-01
HUT62798A (en) 1993-06-28
CA2063598A1 (en) 1991-01-08
DE69010336D1 (de) 1994-08-04
LV10192A (lv) 1994-10-20
AU638992B2 (en) 1993-07-15
JPH04507091A (ja) 1992-12-10
HK1001821A1 (en) 1998-07-10
AU5630890A (en) 1991-02-06

Similar Documents

Publication Publication Date Title
ATE107858T1 (de) Pharmazeutische zusammensetzung zum abnehmen.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
YU47543B (sh) Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE68910159D1 (de) Dosierform für Verabreichung in der Humanmedizin.
BR9006924A (pt) Formulacao para tratamento de sintomas e doencas,uso de formulacao para o tratamento de sintomas e doencas,metodo para o tratamento de sintomas e doencas,distribuicao de agentes medicinais e terapeuticos para o tratamento de sintomas e doencas e combinacao para administracao em mamiferos
PT977564E (pt) Forscolina para promocao da massa corporal magra
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
DE69637050D1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer
SE8802569D0 (sv) Improvements in or relation to somatostatins
EP0214254A1 (de) Melatoninhaltige mittel sowie deren verwendungen.
ES2176495T3 (es) Utilizacion de un antagonista de la bradiquinina, destinada a inducir y/o estimular el crecimiento de los cabellos y/o frenar su caida.
IL126175A (en) Pharmaceutical compositions containing endothelin antagonists and novel endothelin antagonists
IL101675A (en) Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
AR008155A1 (es) Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
GB2004183A (en) Compositions containing caffeine and ephedrine or their derivatives
KR900017599A (ko) 종양 치료용 약학 조성물
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
ES2053834T3 (es) Un metodo para la preparacion de una sustancia terapeutica.
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)
IT1200350B (it) Supporto a pedana per il corpo umano nella pratica dell'idromassaggio adattabile al fondo
IT8819879A0 (it) Composizioni farmaceutiche atte all'impiego nella terapia dell'ipotensione arteriosa.
IT1317079B1 (it) Uso della isovaleril l-carnitina per la preparazione di un medicamentoper la prevenzione e cura dell'osteoporosi.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee